GRAIL (NASDAQ:GRAL) Stock Price Target Raised at Mizuho

25 Sep 2026, 12:42 by Danessa Lincoln · The Markets Daily

GRAIL (NASDAQ:GRAL – Get Free Report) had its price target upped by research analysts at Mizuho from $65.00 to $100.00 in a report issued on Friday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Mizuho’s target price would indicate a potential downside of 20.13% from the stock’s current price.

A number of other equities analysts have also commented on GRAL. Wall Street Zen raised GRAIL from a “sell” rating to a “hold” rating in a research note on Sunday, September 13th. Royal Bank Of Canada began coverage on GRAIL in a report on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 price target for the company. TD Cowen reiterated a “buy” rating on shares of GRAIL in a research report on Thursday. Robert W. Baird increased their price objective on shares of GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a report on Tuesday. Finally, UBS Group set a $84.00 price objective on shares of GRAIL in a research report on Thursday, September 17th. Five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $78.60.

Get Our Latest Stock Analysis on GRAIL

GRAIL Stock Performance

Shares of NASDAQ:GRAL opened at $125.21 on Friday. GRAIL has a 52 week low of $41.50 and a 52 week high of $126.81. The company’s fifty day moving average is $77.33 and its 200-day moving average is $65.25. The company has a market capitalization of $5.59 billion, a PE ratio of -12.84 and a beta of 3.25.

GRAIL (NASDAQ:GRAL – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million during the quarter, compared to analysts’ expectations of $42.39 million. On average, analysts forecast that GRAIL will post -10.41 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Aaron Freidin sold 4,100 shares of GRAIL stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $93.34, for a total value of $382,694.00. Following the completion of the sale, the chief financial officer directly owned 248,983 shares in the company, valued at $23,240,073.22. This trade represents a 1.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Joshua J. Ofman sold 61,452 shares of the business’s stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $97.74, for a total value of $6,006,318.48. Following the sale, the chief executive officer directly owned 362,271 shares of the company’s stock, valued at $35,408,367.54. This represents a 14.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 78,452 shares of company stock valued at $7,485,691. 1.83% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On GRAIL

Several institutional investors have recently modified their holdings of the business. State Street Corp lifted its stake in GRAIL by 26.1% in the second quarter. State Street Corp now owns 2,385,514 shares of the company’s stock valued at $162,859,000 after buying an additional 493,621 shares during the period. The Manufacturers Life Insurance Company boosted its stake in GRAIL by 26.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,597 shares of the company’s stock worth $1,474,000 after acquiring an additional 4,498 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in GRAIL during the second quarter valued at approximately $82,000. Arizona State Retirement System grew its holdings in GRAIL by 8.6% during the second quarter. Arizona State Retirement System now owns 10,470 shares of the company’s stock valued at $715,000 after purchasing an additional 833 shares during the period. Finally, Nykredit A S bought a new stake in GRAIL in the second quarter valued at approximately $96,000.

Key Headlines Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

Positive Sentiment: FDA advisers backed Galleri’s safety and narrowly endorsed the test’s efficacy, improving its prospects for full FDA approval. The close efficacy vote shows that effectiveness remains a key risk, but the recommendation represents an important regulatory milestone. FDA advisers back safety of GRAIL’s cancer test
Positive Sentiment: Galleri’s final FDA decision is expected in the coming months. Approval could expand market access, encourage insurer adoption and materially increase GRAIL’s commercial opportunity. GRAIL’s multi-cancer blood test gets FDA committee vote
Positive Sentiment: The FDA news helped drive a reported 55% weekly rally and pushed GRAIL to a new 52-week high, reflecting increased investor expectations for Galleri. Why GRAIL stock surged this week
Positive Sentiment: Robert W. Baird raised its price target from $96 to $118 and maintained an outperform rating, citing a more favorable regulatory outlook.
Neutral Sentiment: GRAIL also reported PATHFINDER 2 study findings, providing additional clinical data for investors evaluating Galleri’s effectiveness ahead of the FDA’s final decision. GRAIL reports PATHFINDER 2 study findings
Neutral Sentiment: Reported short interest was zero shares as of September 24, suggesting little measurable short-selling pressure, although the figure may reflect a data-reporting issue.
Negative Sentiment: CEO Joshua Ofman sold 61,452 shares worth about $6.0 million, while CFO Aaron Freidin sold 4,100 shares worth approximately $383,000. Both transactions occurred under pre-arranged Rule 10b5-1 plans, reducing their significance but potentially weighing on sentiment. GRAIL insider Joshua Ofman sells shares
Negative Sentiment: Goldman Sachs initiated coverage with a hold rating, while the broader analyst consensus remains hold with an average target of $75.10—well below recent trading levels—indicating valuation and execution concerns after the rally.

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.